Correction to: The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on multidrug-resistant tuberculosis in India and China

BMC Med. 2022 Mar 1;20(1):99. doi: 10.1186/s12916-022-02306-3.

Chathika K Weerasuriya¹, Rebecca C Harris^{2

3}, C Finn McQuaid², Fiammetta Bozzani⁴, Yunzhou Ruan⁵, Renzhong Li⁵, Tao Li⁵, Kirankumar Rade⁶, Raghuram Rao⁷, Ann M Ginsberg^{8

9}, Gabriela B Gomez^#^{4

10}, Richard G White^#²

¹ TB Modelling Group, TB Centre and Centre for the Mathematical Modelling of Infectious Diseases, Department of Infectious Disease Epidemiology, Faculty of Epidemiology & Population Health, London School of Hygiene and Tropical Medicine, London, UK. c.weerasuriya@lshtm.ac.uk.
² TB Modelling Group, TB Centre and Centre for the Mathematical Modelling of Infectious Diseases, Department of Infectious Disease Epidemiology, Faculty of Epidemiology & Population Health, London School of Hygiene and Tropical Medicine, London, UK.
³ Currently employed at Sanofi Pasteur, Singapore, Singapore.
⁴ Department of Global Health and Development, Faculty of Public Health & Policy, London School of Hygiene and Tropical Medicine, London, UK.
⁵ Chinese Centre for Disease Control and Prevention, Beijing, China.
⁶ World Health Organisation, New Delhi, India.
⁷ National Tuberculosis Elimination Programme, New Delhi, India.
⁸ International AIDS Vaccine Initiative, New York, USA.
⁹ Current Affiliation: Bill and Melinda Gates Foundation, Washington, DC, USA.
¹⁰ Currently employed at Sanofi Pasteur, Lyon, France.

^# Contributed equally.

No abstract available

Publication types